Abstract

LBA89 - PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
1542P - Safety of lorlatinib in subgroups of patients from a phase I/II trial
E Felip ... G Peltz
Annals of Oncology | VOL. 30
E Felip, et. al.E Felip ... G Peltz
01 Oct 2019
1576P - Efficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC
... A Siddiqui
Annals of Oncology | VOL. 30
, et. al. ... A Siddiqui
01 Oct 2019
LBA19 - Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations
J Corral ... A Pluzanski
Annals of Oncology | VOL. 30
J Corral, et. al.J Corral ... A Pluzanski
01 Nov 2019
LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042
T.S.K Mok ... J Kobie
Annals of Oncology | VOL. 30
T.S.K Mok, et. al.T.S.K Mok ... J Kobie
01 Dec 2019
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3
M.P Goetz ... S.R.D Johnston
Annals of Oncology | VOL. -
M.P Goetz, et. al.M.P Goetz ... S.R.D Johnston
01 May 2024
Overcoming barriers in biomarker testing. Letter to the Editor regarding: ‘ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe’, by A. Bayle et al.
J García-Foncillas ... A Stenzinger
Annals of Oncology | VOL. -
J García-Foncillas, et. al.J García-Foncillas ... A Stenzinger
01 May 2024
Re: Parker CC, Petersen PM, Cook AD, et al. Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial [NCT00541047]. Ann Oncol. 2024 Apr 5:S0923-7534(24)00105-4
Elio Mazzone ... Francesco Montorsi
Annals of Oncology | VOL. -
Elio Mazzone, et. al.Elio Mazzone ... Francesco Montorsi
01 May 2024
Table of Contents
-
Annals of Oncology | VOL. 35
--
01 May 2024
View more papers